Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...
- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new results from a ...
As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback